WASHINGTON (Dec. 17, 2018)
The Personalized Medicine Coalition (PMC) today congratulates PMC Board member Amy Abernethy, M.D., Ph.D., on her selection as the next Principal Deputy Commissioner of the U.S. Food and Drug Administration (FDA).
Dr. Abernethy, who is currently serving as Chief Medical Officer, Chief Scientific Officer & Senior Vice President, Oncology, at Flatiron Health, will join FDA as the agency is increasingly focused on personalized medicine. PMC’s Personalized Medicine at FDA: 2017 Progress Report shows that personalized medicines accounted for more than 20 percent of all new drugs the agency approved since January of 2014.
Dr. Abernethy has published more than 400 peer-reviewed academic journal articles, many of which examine how aggregated clinical data can support personalized medicine. She is an internationally recognized expert in clinical trials, cancer outcomes research, health policy, patient-reported outcomes, and patient-centered care.
“Dr. Abernethy brings a wealth of experience in integrating patient care, advanced data analytics, and health care policy to an environment that increasingly demands greater personalization to improve outcomes and reduce costs,” said PMC Board Chair Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics.
Prior to her tenure as a Flatiron executive, Dr. Abernethy served as a professor at Duke University School of Medicine. She received her M.D. and completed an internal medicine residency at Duke University.
PMC President Edward Abrahams, Ph.D., praised Dr. Abernethy’s commitment to ensuring that treatments are targeted to those patients who will benefit from them.
“Dr. Abernethy is an avid proponent of personalized medicine who brings years of thinking about and advocating for smarter public policies to transform health care from its current, mostly one-size-fits-all model to one that is personalized, predictive, and preventive,” Abrahams said. “She will be a great asset to an agency that is already committed to that vision.”
Christopher J. Wells
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.